Controlling Antibiotic Adverse Drug Reactions in Cystic Fibrosis
The majority of patients with cystic fibrosis experience at least 1 antibiotic adverse drug reaction.
Obstructive Lung Disease
Long-Term Azithromycin Reduced Need for IV Antibiotics in Cystic Fibrosis
Treatment with azithromycin during a 5-year period was associated with reductions in the use of intravenous antibiotics and pulmonary exacerbations in children with cystic fibrosis.
Elexacaftor-Tezacaftor-Ivacaftor Efficacious for Cystic Fibrosis
The percentage of FEV1 higher was at 4 weeks and through 24 weeks with treatment vs placebo.
FDA Approves Triple Combination Therapy for Cystic Fibrosis
The FDA has approved Trikafta for the treatment of patients aged 12 years and older with cystic fibrosis.
Aspergillosis, ABPA-Related Hospitalizations in Cystic Fibrosis Confer Worse Outcomes
Nearly one-third of patients with cystic fibrosis-related hospitalizations have aspergillosis, which is associated with worse outcomes.
Lumacaftor-Ivacaftor Improves Lung Function in Cystic Fibrosis After 1 Year
After one year of therapy, patients had improved lung function, increased BMI, and a reduced need for intravenous antibiotics.
New Clinical Tool Predicts 1- and 2-Year Mortality in Cystic Fibrosis
A novel clinical tool has been developed that uses patients’ overall health status and the risk for intermittent shock events to predict 1- and 2-year mortality in cystic fibrosis.
Comparing Efficacy of Once vs Thrice Daily Aminoglycosides in Cystic Fibrosis
Once- and thrice-daily treatment with aminoglycosides appear to be equally effective for reducing pulmonary exacerbations in cystic fibrosis.
FDA to Review Elexacaftor, Tezacaftor, Ivacaftor Combination for Cystic Fibrosis
The FDA has accepted for priority review the NDA for elexacaftor, tezacaftor and ivacaftor triple combination regimen for patients with cystic fibrosis.
Novel Triple Combination Therapy for Cystic Fibrosis Submitted for FDA Review
The NDA for the investigational therapy elexacaftor (VX-445), for use in combination with tezacaftor and ivacaftor in the treatment of cystic fibrosis, has been submitted to the FDA.
Next post in Obstructive Lung Disease
